Comment: The results from this phase II trial, which demonstrated an intriguing effect on PFS and a striking change in a subset of patients' bone scans, have provided rationale for the initiation of two large phase III studies: COMET-1, a randomized controlled trial of cabozantinib versus prednisone with a primary endpoint of overall survival, and COMET-2, a randomized placebo-controlled trial of cabozantinib versus mitoxantrone and prednisone with an emphasis on pain and bone-scan response.
Robert Dreicer, MD, MS, FACP, Associate Editor
Dr. Dreicer is the Chair of the Department of Solid Tumor Oncology at Cleveland Clinic in Cleveland, Ohio. He received his Medical Degree and Master of Science from the University of Texasï¿½Houston. He completed internal medicine residency training at Indiana University and a medical oncology fellowship at the University of Wisconsin. He is a fellow of the American College of Physicians. Dr. Dreicer is an academic clinical investigator in the area of urologic oncology. He chairs the bladder subcommittee in the Eastern Cooperative Oncology Group and is a member of the American Board of Internal Medicine, Medical Oncology Subspecialty Board. Dr. Dreicer has been writing for Journal Watch Oncology and Hematology since 2006.